Novo Nordisk Chief Scientific Officer Martin Holst Lange discusses the recent clinical trial results of the company's weight loss obesity shot CagriSema, which delivered less weight loss than Eli Lilly’s tirzepatide. Holst Lange also outlines Novo Nordisk's broader obesity treatment pipeline. He speaks with Bloomberg's Dani Burger.

NATO Secretary General Mark Rutte Talks Russia-Ukraine War, EU Refining Capacity
11:39

Dutch Prime Minister Rob Jetten Talks Perfect Fit at ECB
10:44

Khosla Ventures Founder Vinod Khosla Talks AI Development
13:19